Dallas, TX -- (SBWIRE) -- 02/02/2015 -- The report " Polycystic Ovarian Syndrome - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for polycystic ovarian syndrome. Polycystic ovary syndrome is a situation in which a woman has an imbalance of female sex hormones. Symptoms of polycystic ovary syndrome include infertility, pelvic pain, baldness or thinning hair, acne and oily skin. Women's with polycystic ovary syndrome are at higher risk of diabetes, metabolic syndrome, heart disease and high blood pressure. Polycystic ovary syndrome treatment starts with an appropriate diagnosis. Treatments are then selected on a woman's symptoms, age and future pregnancy plans. Complete Report is Available @ http://www.rnrmarketresearch.com/polycystic-ovarian-syndrome-pipeline-review-h1-2015-market-report.html .

It also reviews key players involved in the therapeutic development for polycystic ovarian syndrome and special features on late-stage and discontinued projects. Companies discussed in this polycystic ovarian syndrome pipeline review H1 2015 report include AstraZeneca PLC, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Merck KGaA, Neurocrine Biosciences, Inc.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269608 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases:
- Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
- Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
- Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations

Table of Contents

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015 7
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Polycystic Ovarian Syndrome - Pipeline by AstraZeneca PLC, H1 2015 16
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 17
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H1 2015 18
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H1 2015 19
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H1 2015 20
Polycystic Ovarian Syndrome - Pipeline by Neurocrine Biosciences, Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 40
Polycystic Ovarian Syndrome - Dormant Projects, H1 2015 41

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015 7
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Explore more reports on Women's Health therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About RnRMarketResearch
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.